Journal
NATURE REVIEWS CANCER
Volume 12, Issue 6, Pages 436-444Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3247
Keywords
-
Categories
Funding
- Spanish Ministry of Science and Innovation (MICINN) [PS09/01401, FR2009-0052, IT2009-0053, PI11/00295]
- Comunidad de Madrid [S2011/BMD-2308, 950344]
- GW Pharmaceuticals
- Schering-Plough
Ask authors/readers for more resources
Various reports have shown that cannabinoids (the active components of marijuana and their derivatives) can reduce tumour growth and progression in animal models of cancer, in addition to their well-known palliative effects on some cancer-associated symptoms. This Opinion article discusses our current understanding of cannabinoids as antitumour agents, focusing on recent insights into the molecular mechanisms of action, including emerging resistance mechanisms and opportunities for combination therapy approaches. Such knowledge is required for the optimization of preclinical cannabinoid-based therapies and for the preliminary clinical testing that is currently underway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available